A Phase 4 interventional study of Dexamethasone in Dry Eye, sponsored by Research Insight LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-03.
Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 5th largest by enrollment, is one of 5 that started in 2021, is one of 12 in phase 4, and was the 15th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2021.
This study's enrollment of 50 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 36 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 16 have an industry lead sponsor. The 10 most frequent:
Research Insight LLC is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Research Insight LLC has 6 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for dry eye flares in comparison to topical loteprednol suspension.
The DEPOT Study (Dry Eye Prescription Options for Therapy): A randomized controlled clinical trial assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert, when placed within the lower eye eyelid canaliculus in comparison to topical loteprednol suspension for the treatment of episodic dry eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months prior to the enrollment visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
Drug: Dexamethasone
25 subjects will be randomized to receive treatment of OTX-DED
Drug: Dexamethasone
Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
Also known as: DEXTENZA
To determine effect of dexamethasone insert
SPEED score at Baseline and Week 2
Time frame: 2 Weeks
To determine the effect of dexamethasone insert
The difference in SPEED questionnaire scores before and 4 weeks after treatment.
Time frame: 4 Weeks
The difference in conjunctival hyperemia
Slit exam to determine ocular hyperemia using the Schulze Scale before and 4 weeks after treatment
Time frame: 4 weeks
The difference in tear break up time (TBUT) before and after treatment
Reduced tear break up time (TBUT) ≤ 10 seconds
Time frame: 4 Weeks
The difference in corneal staining before and after treament
The presence of central or inferior staining defined by the Oxford Scale
Time frame: 4 Weeks
Safety outcome measure
Intraocular pressure at Baseline, Week 2 \& 4
Time frame: At baseline, 2 weeks, and 4 weeks
Plan to share: Yes — IPD results will be shared in publication.
Supporting information: Study protocol
Ran from Aug 2021 to primary completion in Dec 2021, 4 months.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 4 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Research Insight LLC